Relative risk of major and non-major bleeding using direct oral anticoagulants compared with Vitamin K antagonist
| Study | Drug | Risk ratio of major and clinically relevant non-major bleeding events |
| RE-COVER (2009) | Dabigatran | 0.64 (0.48–0.85) |
| RE-COVER II (2014) | Dabigatran | 0.63 (0.47–0.86) |
| EINSTEIN-DVT (2010) | Rivaroxaban | 1.00 (0.80–1.25) |
| EINSTEIN PE (2012) | Rivaroxaban | 0.91 (0.77–1.07) |
| AMPLIFY study (2013) | Apixaban | 0.44 (0.36–0.55) |
| HOKUSAI-VTE (2013) | Edoxaban | 0.83 (0.72–0.95) |
DVT, deep vein thrombosis; VTE, venous thromboembolism.